2023
Genetic Susceptibility to Nonalcoholic Fatty Liver Disease and Risk for Pancreatic Cancer: Mendelian Randomization.
King S, Veliginti S, Brouwers M, Ren Z, Zheng W, Setiawan V, Wilkens L, Shu X, Arslan A, Beane Freeman L, Bracci P, Canzian F, Du M, Gallinger S, Giles G, Goodman P, Haiman C, Kogevinas M, Kooperberg C, LeMarchand L, Neale R, Visvanathan K, White E, Albanes D, Andreotti G, Babic A, Berndt S, Brais L, Brennan P, Buring J, Rabe K, Bamlet W, Chanock S, Fuchs C, Gaziano J, Giovannucci E, Hackert T, Hassan M, Katzke V, Kurtz R, Lee I, Malats N, Murphy N, Oberg A, Orlow I, Porta M, Real F, Rothman N, Sesso H, Silverman D, Thompson I, Wactawski-Wende J, Wang X, Wentzensen N, Yu H, Zeleniuch-Jacquotte A, Yu K, Wolpin B, Duell E, Li D, Hung R, Perdomo S, McCullough M, Freedman N, Patel A, Peters U, Riboli E, Sund M, Tjønneland A, Zhong J, Van Den Eeden S, Kraft P, Risch H, Amundadottir L, Klein A, Stolzenberg-Solomon R, Antwi S. Genetic Susceptibility to Nonalcoholic Fatty Liver Disease and Risk for Pancreatic Cancer: Mendelian Randomization. Cancer Epidemiology Biomarkers & Prevention 2023, 32: 1265-1269. PMID: 37351909, PMCID: PMC10529823, DOI: 10.1158/1055-9965.epi-23-0453.Peer-Reviewed Original ResearchMeSH KeywordsGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansMendelian Randomization AnalysisNon-alcoholic Fatty Liver DiseaseObesityPancreatic NeoplasmsPolymorphism, Single NucleotideConceptsNonalcoholic fatty liver diseasePancreatic cancer riskFatty liver diseasePancreatic cancerCancer riskLiver diseaseGenetic predispositionMendelian randomizationPancreatic Cancer Case-Control ConsortiumConfidence intervalsPancreatic Cancer Cohort ConsortiumPC risk factorsMR methodsRisk factorsGenome-wide association studiesGenetic susceptibilityLogistic regressionCancerMetabolic perturbationsMetabolic conditionsRiskDiseaseGenetic variantsAssociationPredispositionGenetic variants of glucose metabolism and exposure to smoking in African American breast cancer.
Jung S, Papp J, Sobel E, Pellegrini M, Yu H. Genetic variants of glucose metabolism and exposure to smoking in African American breast cancer. Endocrine Related Cancer 2023, 30 PMID: 36705562, PMCID: PMC10095926, DOI: 10.1530/erc-22-0184.Peer-Reviewed Original ResearchMeSH KeywordsBlack or African AmericanBreast NeoplasmsFemaleGenetic Predisposition to DiseaseGenome-Wide Association StudyGlucoseHumansInsulin ResistancePolymorphism, Single NucleotideRisk FactorsSmokingConceptsInsulin resistanceBC riskLifestyle factorsSingle nucleotide polymorphismsAA womenRisk genotypesAfrican American postmenopausal womenAfrican-American breast cancerRisk of BCBreast cancer developmentDose-dependent mannerPostmenopausal womenPositive BCPredictive markerRisk factorsFemale hormonesBreast cancerGlucose metabolismMetabolic biomarkersGene-environment interaction analysisSmokingPreventive interventionsCancer developmentWhite womenIndividual single nucleotide polymorphisms
2014
The KRAS-Variant and miRNA Expression in RTOG Endometrial Cancer Clinical Trials 9708 and 9905
Lee LJ, Ratner E, Uduman M, Winter K, Boeke M, Greven KM, King S, Burke TW, Underhill K, Kim H, Boulware RJ, Yu H, Parkash V, Lu L, Gaffney D, Dicker AP, Weidhaas J. The KRAS-Variant and miRNA Expression in RTOG Endometrial Cancer Clinical Trials 9708 and 9905. PLOS ONE 2014, 9: e94167. PMID: 24732316, PMCID: PMC3986055, DOI: 10.1371/journal.pone.0094167.Peer-Reviewed Original ResearchConceptsEndometrial cancer riskType 2 endometrial cancerEndometrial cancerKRAS-variantCancer riskLymphovascular invasionSurvival outcomesTumor biologyType 1 endometrial cancerEndometrial cancer trialsOverall survival rateMiRNA expressionAge-matched controlsCase-control analysisFunctional germline variantsClinical characteristicsPatient ageTumor characteristicsCancer trialsTumor specimensSurvival rateType 1Germline variantsMiRNA expression levelsCancer
2010
Association of genetic polymorphisms in DNA repair pathway genes with non-small cell lung cancer risk
Qian B, Zhang H, Zhang L, Zhou X, Yu H, Chen K. Association of genetic polymorphisms in DNA repair pathway genes with non-small cell lung cancer risk. Lung Cancer 2010, 73: 138-146. PMID: 21195504, DOI: 10.1016/j.lungcan.2010.11.018.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCarcinoma, Non-Small-Cell LungDNA RepairDNA Repair EnzymesDNA-Binding ProteinsFemaleGenetic Association StudiesGenetic Predisposition to DiseaseHumansLung NeoplasmsMaleMiddle AgedPolymorphism, GeneticRisk FactorsSmokingXeroderma Pigmentosum Group A ProteinXeroderma Pigmentosum Group D ProteinYoung AdultConceptsNon-small cell lung cancerLung cancer riskSquamous cell carcinomaLung cancerCancer riskCell carcinomaSingle nucleotide polymorphismsHigh riskGenetic polymorphismsNon-small cell lung cancer riskRisk of NSCLCCell lung cancer riskHigher lung cancer riskCell lung cancerVariant AA genotypeDominant risk factorNumerous epidemiological studiesLogistic regression modelsDNA repair pathway genesYoung smokersNSCLC casesSubgroup analysisRisk factorsHealthy controlsStratified analysisA KRAS-Variant in Ovarian Cancer Acts as a Genetic Marker of Cancer Risk
Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, Pelletier C, Blitzblau R, Tassi R, Paranjape T, Hui P, Godwin AK, Yu H, Risch H, Rutherford T, Schwartz P, Santin A, Matloff E, Zelterman D, Slack FJ, Weidhaas JB. A KRAS-Variant in Ovarian Cancer Acts as a Genetic Marker of Cancer Risk. Cancer Research 2010, 70: 6509-6515. PMID: 20647319, PMCID: PMC2923587, DOI: 10.1158/0008-5472.can-10-0689.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkers, TumorBreast NeoplasmsCase-Control StudiesFemaleGenes, rasGenetic MarkersGenetic Predisposition to DiseaseGenetic VariationHumansMiddle AgedOvarian NeoplasmsConceptsOvarian cancerKRAS-variantOC patientsCancer riskRisk of OCIndependent case-control analysesCase-control studyOvarian cancer syndromeCase-control analysisFamily membersAdvanced diseaseWomen's cancersRisk factorsBRCA2 mutationsHBOC patientsOC casesIndependent cohortHBOC familiesHereditary breastSolid tumorsCancer syndromesKRAS oncogeneVariant allelesPatientsCancerRacial differences in the association between body mass index and serum IGF1, IGF2, and IGFBP3
Fowke JH, Matthews CE, Yu H, Cai Q, Cohen S, Buchowski MS, Zheng W, Blot WJ. Racial differences in the association between body mass index and serum IGF1, IGF2, and IGFBP3. Endocrine Related Cancer 2010, 17: 51-60. PMID: 19786462, PMCID: PMC2814999, DOI: 10.1677/erc-09-0023.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge of OnsetAgedBlack or African AmericanBody Mass IndexBreast NeoplasmsCross-Sectional StudiesFemaleFollow-Up StudiesGenetic Predisposition to DiseaseHumansInsulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor Binding ProteinsInsulin-Like Growth Factor IInsulin-Like Growth Factor IIMiddle AgedPostmenopausePremenopauseProspective StudiesSoutheastern United StatesWhite PeopleYoung AdultConceptsBody mass indexAge 21 yearsBreast cancer riskIGF1 levelsRace/ethnicityIGFBP3 levelsMass indexWhite womenAA womenCancer riskRacial differencesPremenopausal breast cancer riskAfrican American race/ethnicityLower body mass indexEffect of obesityHigher IGF1 levelsCross-sectional analysisFree IGF1Serum IGF1IGF levelsBMI rangeAge 40Wide BMI rangeProtein 3WomenA genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33
Petersen GM, Amundadottir L, Fuchs CS, Kraft P, Stolzenberg-Solomon RZ, Jacobs KB, Arslan AA, Bueno-de-Mesquita HB, Gallinger S, Gross M, Helzlsouer K, Holly EA, Jacobs EJ, Klein AP, LaCroix A, Li D, Mandelson MT, Olson SH, Risch HA, Zheng W, Albanes D, Bamlet WR, Berg CD, Boutron-Ruault MC, Buring JE, Bracci PM, Canzian F, Clipp S, Cotterchio M, de Andrade M, Duell EJ, Gaziano JM, Giovannucci EL, Goggins M, Hallmans G, Hankinson SE, Hassan M, Howard B, Hunter DJ, Hutchinson A, Jenab M, Kaaks R, Kooperberg C, Krogh V, Kurtz RC, Lynch SM, McWilliams RR, Mendelsohn JB, Michaud DS, Parikh H, Patel AV, Peeters PH, Rajkovic A, Riboli E, Rodriguez L, Seminara D, Shu XO, Thomas G, Tjønneland A, Tobias GS, Trichopoulos D, Van Den Eeden SK, Virtamo J, Wactawski-Wende J, Wang Z, Wolpin BM, Yu H, Yu K, Zeleniuch-Jacquotte A, Fraumeni JF, Hoover RN, Hartge P, Chanock SJ. A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nature Genetics 2010, 42: 224-228. PMID: 20101243, PMCID: PMC2853179, DOI: 10.1038/ng.522.Peer-Reviewed Original Research
2009
Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer
Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, Fuchs CS, Petersen GM, Arslan AA, Bueno-de-Mesquita HB, Gross M, Helzlsouer K, Jacobs EJ, LaCroix A, Zheng W, Albanes D, Bamlet W, Berg CD, Berrino F, Bingham S, Buring JE, Bracci PM, Canzian F, Clavel-Chapelon F, Clipp S, Cotterchio M, de Andrade M, Duell EJ, Fox Jr J, Gallinger S, Gaziano JM, Giovannucci EL, Goggins M, González CA, Hallmans G, Hankinson SE, Hassan M, Holly EA, Hunter DJ, Hutchinson A, Jackson R, Jacobs KB, Jenab M, Kaaks R, Klein AP, Kooperberg C, Kurtz RC, Li D, Lynch SM, Mandelson M, McWilliams RR, Mendelsohn JB, Michaud DS, Olson SH, Overvad K, Patel AV, Peeters PH, Rajkovic A, Riboli E, Risch HA, Shu XO, Thomas G, Tobias GS, Trichopoulos D, Van Den Eeden SK, Virtamo J, Wactawski-Wende J, Wolpin BM, Yu H, Yu K, Zeleniuch-Jacquotte A, Chanock SJ, Hartge P, Hoover RN. Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nature Genetics 2009, 41: 986-990. PMID: 19648918, PMCID: PMC2839871, DOI: 10.1038/ng.429.Peer-Reviewed Original ResearchMeSH KeywordsABO Blood-Group SystemAllelesCase-Control StudiesChromosomes, Human, Pair 9Cohort StudiesFemaleGene FrequencyGenetic Predisposition to DiseaseGenetic VariationGenome-Wide Association StudyGenotypeHaplotypesHumansIntronsLinkage DisequilibriumLogistic ModelsMaleOdds RatioPancreatic NeoplasmsPolymorphism, Single NucleotideProspective StudiesRisk FactorsUnited States
2004
Insulin‐like growth factor‐I gene polymorphism and breast cancer risk in Chinese women
Wen W, Gao Y, Shu X, Yu H, Cai Q, Smith J, Zheng W. Insulin‐like growth factor‐I gene polymorphism and breast cancer risk in Chinese women. International Journal Of Cancer 2004, 113: 307-311. PMID: 15386404, DOI: 10.1002/ijc.20571.Peer-Reviewed Original ResearchConceptsBreast cancer riskBreast cancerPremenopausal womenCancer riskPopulation-based case-control studyAge frequency-matched controlsChinese womenIncident breast cancer casesPlasma IGF-I levelsInsulin-like growth factorIGF-I levelsFrequency-matched controlsCase-control studyBreast cancer casesAssociation of IGFDose-response mannerMeta-analysis resultsBreast cancer susceptibilityIGF-I geneSignificant genetic factorInsulin-like growth factor-I gene polymorphismPlasma IGFCancer casesGeneral populationGene polymorphismsGenetic polymorphisms in the IGFBP3 gene: association with breast cancer risk and blood IGFBP-3 protein levels among Chinese women.
Ren Z, Cai Q, Shu X, Cai H, Li C, Yu H, Gao Y, Zheng W. Genetic polymorphisms in the IGFBP3 gene: association with breast cancer risk and blood IGFBP-3 protein levels among Chinese women. Cancer Epidemiology Biomarkers & Prevention 2004, 13: 1290-5. PMID: 15298948, DOI: 10.1158/1055-9965.1290.13.8.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge DistributionBase SequenceBiomarkers, TumorBreast NeoplasmsCase-Control StudiesChinaConfidence IntervalsFemaleGenetic Predisposition to DiseaseHumansIncidenceInsulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor Binding ProteinsMiddle AgedMolecular Sequence DataOdds RatioPolymerase Chain ReactionPolymorphism, GeneticPopulation SurveillanceReference ValuesRisk AssessmentConceptsInsulin-like growth factorIGFBP-3 protein levelsBreast cancer riskBreast cancerVariant allelesIGFBP3 polymorphismsIGFBP-3IGFBP3 geneCancer riskElevated riskRisk genotypesActions of IGFsIncident breast cancer patientsChinese womenIGFBP-3 levelsIGF binding proteinBreast cancer patientsGenetic polymorphismsIGFBP-3 proteinProtein levelsCase-control studyDose-response mannerCancer patientsOdds ratioPolymorphism A